(b) Details of industrial licences granted along with the capacity approved etc. are being published regularly by the India Investment Centre in their Monthly News Letter copies of which are available in the Parliament Library.

(c) The import policy of a drug is formulated in consideration of several factors including its domestic demand vis-a-vis indigenous production. The import of a drug is normally allowed to fill the gap between the demand and the indigenous production.

(d) No, Sir.

(e) Does not arise.

Import of Telecommunication Equipment

987. SHRI BHAGATRAM MANHAR: Will the Minister of COMMUNICATIONS be pleased to state:

(a) whether Government have placed orders for purchase of telecommunication equipments from foreign companies in the years 1985 and 1986;

(b) what is the name of foreign company, contract value, contract date, delivery schedule, nature and number of equipment involved in the case of each order placed so far;

(c) what has been the indigenous production for each of such imported equipment in each year from 1982 to 1985; and

(d) what specific steps have been taken by Government to indigenise the production in the case of each such equipment?

THE MINISTER OF STATE OF THE MINISTRY OF COMMUNICATIONS (SHRI RAM NIWAS MIRDHA): (a) to (d) The information is being collected and will be laid on the table of the House shortly.

Imported Value of Telecommunication Equipment

988 SHRI BHAGATRAM MANHAR: Will the Minister of COMMUNICATIONS be pleased to state:

(a) the names of the countries from which India has imported telecommunication equipment for each year from 1980 to 1985;

(b) value of imports from each country for each of these five years;

(c) nature of telecommunication equipment supplied by each of these countries during each year;

(d) what would be the total quantity and value of imports of each of the telecommunication equipment in each year from 1980 to 1985; and

(e) what are the projections for imports of each telecommunications equipment in 1986-87?

THE MINISTER OF STATE OF THE MINISTRY OF COMMUNICATIONS (SHRI RAM NIWAS MIRDHA): (a) to (e) The information is being collected and will be laid on the table of the House shortly.

Prices of Betamethason and its Salts

989. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to state:

(a) when the prices of Betamethason and its salts as well as its formulations were notified by his Ministry under DPCO, 1979;

(b) when did M/s. Glaxo obtained stay order against this notification.

(c) what are the issues pending before Court and what are the reasons for delay;

(d) what special efforts were made by his Ministry to get the case expedited;

(e) whether it is a fact that M/s. Glaxo is interested to get the case delayed and the department is helping in this regard;

(f) whether it is also a fact that M/s. Glaxo is utilising an amount

around twenty five crores without interest as working capital which is due to public; and

(g) what steps his department have taken to save the consumer from being charged high prices by providing the essential medicines at fair prices?

THE MINISTER OF STATE IN THE DEPARTMENT OF INDUSTRIAL DEVELOPMENT (SHRI M. ARUNACHALAM): (a) The price of Betamethason and its salts were notified under the Drugs (Prices Control) Order, 1979 on 12th May, 1981. Before any change in the formulation prices could be effected, the company obtained a Stay from the Delhi High Court.

(b) Stay against the notified prices of Betamenthasone and its salts and proposed changes in the prices of formulations was granted by the Delhi High Court on 1st July, 1981.

(c) The company have inter-alia challenged the reduction in prices of Betamethasone and its salts and the proposed reduction in prices of formulations in the Writ Petition. The matter is yet to come up for final hearing.

(d) My Ministry is constantly making efforts to have the final hearing of this case expedited in the High Court.

(e) It is the prerogative of the High Court to list the matter for hearing at any time it desires.

(f) and (g) M/s. Glaxo Laboratories (India) Limited have shown Drugs Prices Equalisation Account Liability of Rs. 2105.99 lakhs upto 30th June, 1985 under the head 'Current Liabilities' in their Annual Report for that year. The purpose for which the amount has been utilised or is being utilised is not known. As the matter is subjudice, no action can be taken to enforce the price of Betamethasone and formulations by th Government at this stage.

Working capital of M/s. Glaxo

990. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to state:

(a) what was the total cost of sale of Glaxo Laboratories during the last three years;

(b) what is the actual working capital obtained by the company from banking institutions during this period.

(c) whether it is a fact that large amounts shown as current liabilities to Drugs Equalisation Account has been unauthorisedly diverted by the company and used as working capital;

(d) what is the extent of bank interest which the company has saved by using the DPEA liability as working capital; and

(e) what is the total amount due under DPEA at present and what efforts have been made to recover this amount which runs into several crores?

THE MINISTER OF STATE IN THE DEPARTMENT OF INDUSTRIAL DEVELOPMENT (SHRI M. ARUNACHALAM): (a) to (e) Information to the extent available would be collected and laid on the Table of the Rajya Sabha.

Import of technology and heavy machinery

991. SHRI RAMCHANDRA BHARADWAJ): Will the Minister of INDUSTRY be pleased to state:

(a) whether Government's attention has been drawn to the reports that consequent on liberalisation of import policy, various electricity boards and undertakings are importing technology and heavy machinery for power generation;

(b) if so, whether as a result of this trend the order-list for power generating equipment with the Bharat